- Home
- IBIO vs BCDA Comparison
IBIO vs BCDA Comparison
Compare IBIO & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- BCDA
- Stock Information
- Founded
- IBIO 2008
- BCDA N/A
- Country
- IBIO United States
- BCDA United States
- Employees
- IBIO N/A
- BCDA N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- BCDA Health Care
- Exchange
- IBIO Nasdaq
- BCDA Nasdaq
- Market Cap
- IBIO 11.9M
- BCDA 11.3M
- IPO Year
- IBIO N/A
- BCDA N/A
- Fundamental
- Price
- IBIO $0.93
- BCDA $2.16
- Analyst Decision
- IBIO Strong Buy
- BCDA Strong Buy
- Analyst Count
- IBIO 2
- BCDA 1
- Target Price
- IBIO $5.50
- BCDA $25.00
- AVG Volume (30 Days)
- IBIO 2.1M
- BCDA 45.6K
- Earning Date
- IBIO 11-11-2025
- BCDA 11-12-2025
- Dividend Yield
- IBIO N/A
- BCDA N/A
- EPS Growth
- IBIO N/A
- BCDA N/A
- EPS
- IBIO N/A
- BCDA N/A
- Revenue
- IBIO $400,000.00
- BCDA N/A
- Revenue This Year
- IBIO N/A
- BCDA N/A
- Revenue Next Year
- IBIO N/A
- BCDA N/A
- P/E Ratio
- IBIO N/A
- BCDA N/A
- Revenue Growth
- IBIO 77.78
- BCDA N/A
- 52 Week Low
- IBIO $0.56
- BCDA $1.63
- 52 Week High
- IBIO $6.89
- BCDA $3.26
- Technical
- Relative Strength Index (RSI)
- IBIO 64.71
- BCDA 59.44
- Support Level
- IBIO $0.77
- BCDA $1.90
- Resistance Level
- IBIO $0.97
- BCDA $2.29
- Average True Range (ATR)
- IBIO 0.07
- BCDA 0.09
- MACD
- IBIO 0.01
- BCDA 0.04
- Stochastic Oscillator
- IBIO 82.62
- BCDA 66.67
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).